NGL Fine-Chem (NSE:NGLFINE) Total Current Liabilities: ₹1,500 Mil (As of Mar. 2026)


NSE:NGLFINE NGL Fine-Chem Ltd NSE:NGLFINE
78 GF Score
Price ₹3,224.60
GF Value ₹2,821.59
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is NGL Fine-Chem Total Current Liabilities?

NGL Fine-Chem NSE:NGLFINE +4.28% 78 Total Current Liabilities is ₹1,500 Mil as of Mar. 2026. GuruFocus rates NSE:NGLFINE with a GF Score™ of 78/100 and a GF Value™ of ₹2,821.59 (Modestly Overvalued). The stock has 8 warning signs investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. NGL Fine-Chem's total current liabilities for the quarter that ended in Mar. 2026 was ₹1,500

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

NGL Fine-Chem Total Current Liabilities Related Terms

NGL Fine-Chem Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for NGL Fine-Chem's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NGL Fine-Chem Total Current Liabilities Chart

NGL Fine-Chem Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 656.50 582.92 865.87 1,189.70 1,500.14

NGL Fine-Chem Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,189.70 0.00 1,405.14 0.00 1,500.14
NSE:NGLFINE
78GF Score
NGL Fine-Chem Ltd NSE:NGLFINE
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NGL Fine-Chem Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

NGL Fine-Chem's Total Current Liabilities for the fiscal year that ended in Mar. 2026 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=665.27+521.02
+Other Current Liabilities+Current Deferred Liabilities
=313.849+0
=1,500

NGL Fine-Chem's Total Current Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=665.27+521.02
+Other Current Liabilities+Current Deferred Liabilities
=313.849+0
=1,500

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of ₹1,500 Mil mean?
NGL Fine-Chem (NSE:NGLFINE) has a Total Current Liabilities of ₹1,500 Mil as of Mar. 2026. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for NGL Fine-Chem and its competitors.
Is NGL Fine-Chem's Total Current Liabilities too high?
NGL Fine-Chem's current Total Current Liabilities is ₹1,500 Mil. Overall, NGL Fine-Chem has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NGL Fine-Chem's Total Current Liabilities compare to LLY and JNJ?
NGL Fine-Chem's Total Current Liabilities of ₹1,500 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Drug Manufacturers company?
A good Total Current Liabilities depends on the Drug Manufacturers industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for NGL Fine-Chem and its competitors. NGL Fine-Chem's current Total Current Liabilities is ₹1,500 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NGL Fine-Chem stock overvalued right now?
Based on GuruFocus' analysis, NGL Fine-Chem (NSE:NGLFINE) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,821.59, compared to a current price of ₹3,224.60 — trading 14.3% above its estimated fair value. The current Total Current Liabilities is ₹1,500 Mil. NGL Fine-Chem's overall GF Score™ is 78/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For NGL Fine-Chem (NSE:NGLFINE), the current Total Current Liabilities is ₹1,500 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NGL Fine-Chem (NSE:NGLFINE) Overvalued in 2026?

Based on GuruFocus' analysis, NGL Fine-Chem stock appears to be overvalued. The current stock price of ₹3,224.60 is trading 14.3% above its estimated GF Value™ of ₹2,821.59. GuruFocus considers NGL Fine-Chem to be Modestly Overvalued.

Key valuation signals for NSE:NGLFINE:

  • Total Current Liabilities: ₹1,500 Mil
  • GF Value™: ₹2,821.59 vs. price of ₹3,224.60 (14.3% above fair value)
  • GF Score™: 78/100 with 8 warning signs

No single metric tells the full story. See the NSE:NGLFINE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NGL Fine-Chem Business Description

Other Exchanges 524774:India
Address 301, E Square, Subhash Road, Vile Parle (East), Mumbai, MH, IND, 400057
NGL Fine-Chem Ltd is an Indian company engaged in the pharmaceutical business. It is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health, catering to various companies to custom-manufacture pharmaceuticals. The company's product portfolio comprises animal health APIs such as homidium chloride, nitroxynil, clorsulon, decoquinate, fenbendazole, etc.; human health APIs such as nitazoxanide and atovaquone; drug intermediates and specialty chemicals; and finished dosage forms such as diminazene aceturate granules and homidium chloride tablets. Geographically, the group generates maximum revenue from the Asia-Pacific region, and the rest from India, Europe, the USA, and the rest of the world.
78GF Score

Get the complete analysis for NSE:NGLFINE

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹3,224.60
Price
₹2,821.59
GF Value